Search Results

The QuickVue One-Step hCG-Urine is a one-step immunoassay intended for the qualitative detection of human Chorionic Gonadotropin (hCG) in urine for the early detection of pregnancy. The test is intended for use by health care professionals.

The test is a rapid immunoassay for the qualitative detection of hCG in urine. Urine is added to the Sample Well on the Test Cassette. Shortly after addition of the sample, a blue procedural Control Line will appear in the Result Window. If hCG is present in the sample, a pink-to-red Test Line will also appear. If hCG is not present, only the blue procedural Control Line will appear.

Here's a breakdown of the acceptance criteria and study information for the Quidel QuickVue® One-Step hCG-Urine device, based on the provided text:

Acceptance Criteria and Device Performance

The document doesn't explicitly list numerical acceptance criteria in a table format, but it describes the types of studies performed and the qualitative outcomes. The primary implicit acceptance criterion is "substantial equivalence" to legally marketed predicate devices, supported by demonstrating similar performance characteristics.

Study Details

2. Sample size used for the test set and the data provenance:

• Test Set Sample Size: Not explicitly stated as a number of individual samples. The text mentions "Using samples obtained from women presenting for pregnancy testing" for the accuracy study.
• Data Provenance:
  • Country of origin of the data: Not explicitly stated, but the manufacturer is based in the U.S. (San Diego, CA, U.S.A.), indicating the studies likely took place in the U.S.
  • Retrospective or Prospective: Not explicitly stated, but the "samples obtained from women presenting for pregnancy testing" for the accuracy study suggests a prospective collection from a clinical setting. The Physicians' Office studies would also be prospective.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:

• Number of Experts: Not explicitly stated.
• Qualifications of Experts: Not explicitly stated. However, for the accuracy study, the comparator was a "commercially available qualitative hCG test." The " Physicians' Office studies" involved "physician office personnel with diverse educational backgrounds and work experience," implying general healthcare workers capable of performing point-of-care tests.

4. Adjudication method for the test set:

• Adjudication Method: Not explicitly stated. For the accuracy study, "a direct comparison of the test to a commercially available qualitative hCG test was conducted," implying the commercial test served as the reference or ground truth, rather than an explicit adjudication process for disagreements between human readers.

5. If a multi reader multi case (MRMC) comparative effectiveness study was done, and the effect size of how much human readers improve with AI vs without AI assistance:

• MRMC Study: No, this device is a rapid in vitro diagnostic immunoassay, not an AI-assisted diagnostic device. Therefore, a multi-reader multi-case (MRMC) comparative effectiveness study with AI assistance is not applicable.
• Effect Size: N/A (not an AI-assisted device).

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done:

• Standalone Performance: Yes, in a sense. The QuickVue device itself is a standalone test that produces a result (presence or absence of a line) without continuous human interaction during the reaction phase, after the user adds the sample. The "accuracy exceeding 99%" was based on the device's output compared to a reference test. The "Physicians' Office studies" looked at how human users perform the standalone test accurately and reproducibly.

7. The type of ground truth used:

• Type of Ground Truth: The primary ground truth for the accuracy study was the result from a "commercially available qualitative hCG test." This is a form of reference standard comparison against an accepted predicate device.
• For the precision and consistency studies, the ground truth would be expected values, which implies a controlled laboratory setting (e.g., gravimetric or volumetric standards, or established reference materials).

8. The sample size for the training set:

• Training Set Sample Size: Not applicable. This is not an AI/machine learning device that requires a training set in that sense. The "training" in the context of this immunoassay would be the internal development and optimization of the assay components and parameters.

9. How the ground truth for the training set was established:

• Ground Truth for Training Set: Not applicable, as it's not an AI device. The development process would involve extensive experimentation and quality control against known positive and negative hCG samples with established concentrations to optimize sensitivity, specificity, and other analytical performance characteristics.

Ask a specific question about this device

The QuickVue® One-Step hCG-Urine is a one-step immunoassay intended for the qualitative detection of human chorionic gonadotropin (hCG) in urine for the early detection of pregnancy. The QuickVue One-Step hCG-Urine is intended for use by health care professionals.

The test is a rapid immunoassay for the qualitative detection of hCG in urine. This test is to be used for the early detection of pregnancy. The test, a lateral-flow immunoassay, employs monoclonal and polyclonal antibodies. Shortly after addition of the urine sample, a blue procedural Control Line will appear. If hCG is present in the sample, a pink-to-purple Test Line will also appear. The result is read at three minutes. If no blue procedural Control Line develops, the result is considered invalid.

Here's a breakdown of the acceptance criteria and study information for the QuickVue® One-Step hCG-Urine device based on the provided text:

1. Table of Acceptance Criteria and Reported Device Performance

2. Sample Size Used for the Test Set and Data Provenance

• Sample Size: Not explicitly stated for the primary accuracy study comparing the QuickVue® device to other FDA-cleared devices. It mentions "Using urine samples obtained from women presenting for pregnancy testing."
• Data Provenance:
  • Accuracy Study: Urine samples from women presenting for pregnancy testing (implicitly prospective data collection, but not explicitly stated as such, suggesting real-world clinical samples).
  • Physician's Office Laboratory Studies: Conducted at "three geographically distinct sites in the United States." This implies retrospective use of existing samples or prospective collection within those sites, but the exact collection method isn't detailed.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of those Experts

This information is not provided in the given text. For a qualitative hCG test, the "ground truth" would typically come from a reference method or a panel of experts confirming pregnancy status, but the details are absent.

4. Adjudication Method for the Test Set

This information is not provided in the given text.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

• No MRMC study was done. This device is an in-vitro diagnostic (IVD) rapid immunoassay for qualitative detection of hCG in urine, not an AI-assisted diagnostic tool requiring human reader interpretation in the context of an MRMC study. The "readers" would be the healthcare professionals performing and interpreting the test based on the color change. The Physician's Office Laboratory studies assessed the reproducibility and accuracy of personnel.

6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) was done

• Yes, a standalone study was done in the sense that the device itself, as an immunoassay, produces a result (color change) that is then interpreted. The "accuracy exceeding 99%" was reported for the device's performance against FDA-cleared predicate devices. The Physician's Office Laboratory studies evaluate human interpretation of the device's standalone output.

7. The Type of Ground Truth Used

• The ground truth for the accuracy study comparing the QuickVue® device was based on results from "other FDA-cleared devices for qualitative hCG detection." This implies a comparison to established, legally marketed diagnostic tests that themselves have a defined accuracy against the biological presence of hCG.
• For the Physician's Office Laboratory studies, the ground truth was referred to as "expected results." This likely refers to a pre-determined or confirmed pregnancy status of the urine samples used.

8. The Sample Size for the Training Set

This information is not provided in the given text. As the device is an immunoassay (not an AI/ML algorithm), the concept of a "training set" in the context of machine learning does not directly apply. The development would involve analytical verification and validation using various concentrations of hCG and negative controls.

9. How the Ground Truth for the Training Set was Established

This information is not provided and is not applicable in the typical AI/ML sense. For immunoassay development, ground truth for validation samples (analogous to a "training set" in a very loose sense for analytical performance) would be established by preparing samples with known concentrations of hCG and negative controls, and potentially using a highly sensitive and specific reference method.

Ask a specific question about this device